Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.
Fewer people in the U.S. are drinking alcohol these days. The holidays have long been a season to overindulge, whether that means too many glasses of wine or too many cookies. But this year may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback